FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds which are irreversible PI3-kinase inhibitors, and conjugates containing one or more PI3-kinases, containing cysteine residue, which is covalently and irreversibly boned with PI3-kinase inhibitor. Invention also discloses pharmaceutical compositions containing said compounds.
EFFECT: compounds are intended for treating disorders and diseases associated with PI3-kinase.
19 cl, 16 dwg, 26 tbl, 52 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROARYL COMPOUNDS AND USING THEM | 2009 |
|
RU2536584C2 |
OXOALKYILIDENE COMPLEXES OF TUNGSTEN FOR Z-SELECTIVE OLEFINES METHATHESIS | 2012 |
|
RU2634708C9 |
INHIBITORS OF PROTEASE OF HEPATITIS C VIRUS AND THEIR APPLICATION | 2008 |
|
RU2515318C2 |
AZAINDOLES, USEFUL AS INHIBITORS OF JAK AND OTHER PROTEINKINASES | 2005 |
|
RU2403252C2 |
INHIBITORS OF PROTEASE OF HEPATITIS C VIRUS AND THEIR APPLICATION | 2008 |
|
RU2523790C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2434871C2 |
HETEROARYL COMPOUNDS AND USE THEREOF | 2009 |
|
RU2734822C2 |
COMPOUNDS APPLICABLE FOR NEURODEGENERATIVE DISORDERS | 2006 |
|
RU2461562C2 |
PYRROLOPYRAZINES SUITABLE AS AURORA A KINASE INHIBITORS | 2005 |
|
RU2394825C2 |
Authors
Dates
2016-08-27—Published
2010-09-09—Filed